Advancing Genomics Through Accessible Indigenous Biotech

In a conversation with Industry Outlook, Ankita Kumari, Founder, Xploregen Discoveries, highlights the rapid growth of India’s genomics ecosystem. She discusses advancements in sequencing, precision medicine, and data analytics, while emphasizing the need to address affordability, infrastructure, and talent gaps to drive wider adoption and global competitiveness.

India’s genomics ecosystem is gaining momentum. What key factors are driving this growth across research, healthcare, and diagnostics?

India's genomics ecosystem is experiencing unprecedented growth, driven by a combination of technological advancements, increased awareness, government support, and the growing need for precision healthcare solutions.

One of the primary drivers is the rapid reduction in sequencing costs. Technologies such as Next-Generation Sequencing (NGS) have become significantly more affordable and accessible, enabling researchers, hospitals, and diagnostic laboratories to incorporate genomics into routine workflows. This has expanded the use of genomic data beyond research laboratories into clinical and diagnostic settings.

Another major factor is the increasing focus on personalized and precision medicine. Healthcare providers are recognizing that genomic information can help predict disease risk, guide treatment decisions, and improve patient outcomes. This has led to greater adoption of genomic testing in areas such as oncology, rare disease diagnosis, reproductive health, and pharmacogenomics.

India's strong research ecosystem has also contributed significantly. Academic institutions, research organizations, and biotechnology companies are actively undertaking large-scale genomic studies, generating valuable insights into the genetic diversity of the Indian population. These efforts are creating datasets that are crucial for developing population-specific diagnostics and therapeutic strategies.

Government initiatives have played an important role as well. Programs focused on biotechnology innovation, genomic surveillance, healthcare modernization, and research funding have strengthened infrastructure and encouraged collaboration between academia, industry, and healthcare institutions. Such initiatives are helping build a sustainable genomics ecosystem within the country.

The growth of bioinformatics and data analytics has further accelerated the field. Modern genomics generates vast amounts of data, and advances in computational biology, artificial intelligence, and cloud computing have made it possible to analyze and interpret this information efficiently. The integration of biology with data science is creating new opportunities across research and diagnostics.

Additionally, the COVID-19 pandemic highlighted the importance of genomics in public health. Genomic surveillance played a critical role in tracking viral variants and understanding disease transmission patterns, increasing awareness among policymakers, healthcare professionals, and the public about the value of genomic technologies.

Finally, the emergence of innovative Indian biotechnology companies and startups has strengthened the ecosystem by providing end-to-end genomic solutions, from sample processing and sequencing to bioinformatics analysis and interpretation. This has reduced dependency on international services and made genomic technologies more accessible to researchers and clinicians across the country.

Together, these factors are positioning India as a rapidly growing hub for genomics research, healthcare innovation, and advanced molecular diagnostics, with significant potential to impact both national and global healthcare outcomes.

Despite progress, accessibility and affordability remain concerns in genomics. What are the key challenges the industry must address to make these technologies more widely available?

While the genomics industry has made significant progress over the past decade, accessibility and affordability remain important challenges, particularly in a country as diverse and populous as India. To truly unlock the potential of genomics, the industry must address several critical barriers.

First, the cost of genomic testing and analysis, although significantly reduced compared to the past, can still be prohibitive for many patients, researchers, and smaller healthcare institutions. Beyond sequencing itself, expenses related to sample logistics, data analysis, interpretation, and infrastructure often add to the overall cost. Continued technological innovation, automation, and economies of scale will be essential to further reduce these costs.

Second, there is a need for greater awareness and education among healthcare professionals and the general public. Many clinicians are still unfamiliar with the practical applications of genomics in routine patient care, which can limit adoption. Building genomic literacy through training programs, medical education, and outreach initiatives will be crucial for broader integration into healthcare systems.

Another significant challenge is the shortage of skilled professionals. Genomics is inherently interdisciplinary, requiring expertise in molecular biology, genetics, bioinformatics, data science, and clinical interpretation. As demand for genomic services grows, developing a workforce capable of handling these complex requirements becomes increasingly important.

With your journey spanning technical, operational, and leadership roles in genomics, how have you seen the biotech industry in India evolve over the years?

Over the course of my career, I have witnessed a remarkable transformation in India's biotechnology and genomics landscape. When I began my journey, genomics services were relatively niche, with limited awareness, high dependency on international service providers, and restricted access to advanced sequencing technologies. Today, India has emerged as a significant player in the global biotechnology ecosystem, driven by advancements in next-generation sequencing (NGS), bioinformatics, precision medicine, agricultural genomics, and biotechnology-driven research.

One of the most significant changes has been the democratization of genomic technologies. Sequencing costs have reduced dramatically, making genomic analysis accessible not only to large research institutions but also to startups, academic laboratories, hospitals, and agricultural organizations. This has accelerated research and enabled wider adoption of genomics in healthcare, diagnostics, drug discovery, and biodiversity studies.

I have also observed a growing emphasis on indigenous innovation. Earlier, many organizations relied heavily on imported technologies and services. Today, Indian companies are developing their own solutions, establishing advanced sequencing facilities, and contributing to global scientific research. Government initiatives supporting biotechnology startups, research infrastructure, and innovation have further strengthened the ecosystem.

From an operational perspective, the industry has become much more quality-driven and data-centric. The integration of automation, digital laboratory management systems, and sophisticated bioinformatics pipelines has significantly improved efficiency and reliability. At the same time, the demand for skilled professionals who can bridge biology, technology, and data science has increased substantially.

As someone who has worked across technical, operational, and leadership roles, I believe the future of Indian biotechnology lies in translating genomic discoveries into practical applications that benefit healthcare, agriculture, environmental sustainability, and personalized medicine. The industry's evolution has been inspiring, and I am excited to contribute to its continued growth through organizations like Biokart India and Xploregen Discoveries.

Infrastructure disparities also need to be addressed. While major metropolitan cities often have access to advanced genomic facilities, researchers and healthcare providers in smaller cities and rural regions may face limitations in terms of laboratory infrastructure, logistics, and technical support. Expanding access through decentralized testing networks and collaborative partnerships can help bridge this gap.

Data management and interpretation present another challenge. Genomic testing generates vast amounts of data, and converting that data into clinically meaningful insights requires robust bioinformatics capabilities and high-quality reference databases. For a genetically diverse population like India, building comprehensive population-specific genomic databases is essential to improve the accuracy and relevance of genomic interpretation.

Regulatory frameworks and quality standardization are equally important. As genomic testing becomes more widespread, ensuring consistency, accuracy, data privacy, and ethical use of genetic information will require strong regulatory oversight and industry-wide quality standards.

Finally, collaboration will be key. No single organization can address these challenges alone. Strong partnerships between industry, academia, healthcare institutions, government agencies, and technology providers are necessary to create an ecosystem that is both innovative and inclusive.

I believe that making genomics widely accessible is not just about reducing costs—it is about creating an integrated ecosystem that combines affordability, infrastructure, education, skilled talent, quality standards, and scientific innovation. If we can successfully address these areas, genomics has the potential to transform healthcare and research for millions of people across India.

Your experience across both scientific and business functions offers a unique perspective. How important is it today for biotech professionals to combine technical expertise with business understanding?

In today's biotechnology industry, the ability to combine technical expertise with business understanding is no longer an advantage—it is a necessity. The sector is evolving rapidly, and successful professionals must be able to bridge the gap between scientific innovation and real-world implementation.

Throughout my career, I have had the opportunity to work across laboratory operations, genomics services, business development, project management, and organizational leadership. This experience has taught me that even the most groundbreaking scientific discoveries can only create meaningful impact when they are translated into sustainable products, services, or solutions that address market and societal needs.

Technical expertise remains the foundation of biotechnology. A strong understanding of molecular biology, genomics, diagnostics, and emerging technologies is essential for driving innovation and maintaining scientific rigor. However, professionals must also understand factors such as market demand, customer requirements, regulatory compliance, operational efficiency, financial sustainability, and strategic planning. These elements determine whether a scientific idea can successfully reach researchers, clinicians, patients, or industry stakeholders.

The genomics sector provides an excellent example. Developing advanced sequencing capabilities is important, but organizations must also understand how to build scalable workflows, manage costs, ensure quality, communicate value to customers, and adapt to changing market dynamics. Professionals who can appreciate both the scientific and business dimensions are often better positioned to make informed decisions and drive organizational growth.

Another reason this combination is becoming increasingly important is the rise of interdisciplinary collaboration. Today's biotechnology projects often involve scientists, bioinformaticians, clinicians, engineers, investors, policymakers, and business leaders working together. Professionals who can effectively communicate across these domains help accelerate innovation and improve outcomes.

For young biotech professionals, I would strongly encourage developing both scientific depth and business awareness. This does not mean everyone needs to become a business manager, but understanding concepts such as project management, commercialization, intellectual property, regulatory pathways, and customer engagement can significantly enhance career opportunities and leadership potential.

In my view, the future leaders of biotechnology will be those who can successfully integrate scientific excellence with strategic thinking. The ability to understand both the science behind an innovation and the pathway to deliver it effectively to society is what ultimately drives meaningful and lasting impact in the biotechnology industry.

In areas like molecular biology and sequencing, where precision is critical, what are the biggest capability or infrastructure gaps still present in India?

In areas such as molecular biology and sequencing, India has made tremendous progress over the last decade, but several capability and infrastructure gaps still need to be addressed to fully realize the country's potential as a global genomics hub.

One of the most significant gaps is the uneven distribution of advanced infrastructure. While major metropolitan cities and leading research institutions have access to state-of-the-art sequencing platforms and molecular biology facilities, many Tier-2 and Tier-3 cities still face limitations in accessing high-end genomic technologies. This creates disparities in research opportunities, diagnostics, and healthcare delivery across regions.

Another critical challenge is the shortage of highly skilled talent, particularly in specialized domains such as bioinformatics, genomic data interpretation, computational biology, and clinical genomics. While India produces a large number of life science graduates every year, there remains a gap between academic training and industry requirements. Greater emphasis on hands-on training, interdisciplinary education, and industry-academia collaboration is needed to build a workforce capable of supporting advanced genomic applications.

Bioinformatics infrastructure is another area that requires significant investment. Modern sequencing technologies generate enormous volumes of data, and extracting meaningful insights from this data requires robust computational resources, secure data storage systems, high-performance computing environments, and sophisticated analytical pipelines. Strengthening these capabilities will be essential as genomic data generation continues to grow.

From a clinical perspective, there is still a need for more comprehensive Indian population-specific genomic databases. Many existing genomic reference datasets are heavily influenced by Western populations, which can sometimes limit the accuracy of variant interpretation for Indian patients. Expanding genomic studies focused on India's diverse population will help improve diagnostic precision and support the development of personalized healthcare solutions.

Quality standardization and accreditation also remain important areas for improvement. As the number of molecular diagnostic and sequencing laboratories increases, maintaining consistent quality, reproducibility, and regulatory compliance becomes increasingly critical. Establishing and adhering to globally recognized quality standards will help strengthen confidence in genomic testing and research outcomes.

Another challenge is the limited integration between research, diagnostics, and healthcare systems. In many cases, valuable genomic findings generated through research do not seamlessly translate into clinical practice. Creating stronger collaborations among research institutions, hospitals, diagnostic laboratories, and industry partners can accelerate the adoption of genomics in routine healthcare.

Additionally, dependence on imported instruments, reagents, and consumables continues to affect costs and supply chain resilience. Encouraging indigenous manufacturing and innovation in genomics technologies can help reduce costs, improve accessibility, and strengthen India's self-reliance in this strategically important sector.

Despite these challenges, I am optimistic about the future. India possesses exceptional scientific talent, a rapidly growing biotechnology ecosystem, and increasing government and private-sector investment in genomics. By strengthening infrastructure, developing skilled human resources, expanding bioinformatics capabilities, and fostering collaboration across the ecosystem, India is well-positioned to become a global leader in molecular biology, sequencing, and precision medicine in the coming years.

As India pushes towards self-reliance in biotech, how important is the development of indigenous solutions such as kits, reagents, and research tools?

The development of indigenous biotechnology solutions is absolutely critical for India's long-term growth, competitiveness, and self-reliance in the life sciences sector. As biotechnology becomes increasingly important for healthcare, agriculture, environmental sustainability, and scientific research, the ability to develop and manufacture our own kits, reagents, instruments, and research tools is both a strategic and economic necessity.

For many years, a significant portion of India's biotechnology ecosystem relied heavily on imported products. While these technologies have played an important role in advancing research and diagnostics, dependence on external suppliers often leads to higher costs, longer procurement timelines, supply chain vulnerabilities, and limited customization for local requirements. The disruptions experienced during the COVID-19 pandemic clearly demonstrated the importance of having robust domestic capabilities in biotechnology manufacturing and innovation.

Indigenous development offers several advantages. First, it improves affordability. Locally developed kits and reagents can significantly reduce costs for research institutions, diagnostic laboratories, academic organizations, and healthcare providers. Lower costs ultimately translate into greater accessibility and wider adoption of advanced technologies.

Second, indigenous solutions can be tailored to address India's specific needs. Whether it is developing diagnostic assays relevant to regional disease profiles, creating genomics tools optimized for Indian population studies, or supporting agricultural biotechnology applications, local innovation enables solutions that are better aligned with our unique challenges and opportunities.

Third, domestic manufacturing strengthens supply chain resilience. Biotechnology research and diagnostics depend on uninterrupted access to high-quality consumables and reagents. Building local production capabilities reduces dependence on global supply chains and ensures continuity during periods of international disruption.

From an innovation perspective, indigenous product development also fosters a culture of scientific entrepreneurship. It encourages collaboration between academia, industry, and research institutions, creating opportunities for startups and established companies to translate scientific knowledge into commercially viable products. This not only strengthens the biotechnology ecosystem but also generates employment, attracts investment, and enhances India's global competitiveness.

At organizations like Biokart India and Xploregen Discoveries, we strongly believe that developing and supporting indigenous biotechnology solutions is essential for the future of the industry. While global collaboration and technology exchange will always remain important, India must continue investing in its own research, product development, manufacturing capabilities, and intellectual property generation.

As India moves toward becoming a global biotechnology powerhouse, the success of indigenous kits, reagents, research tools, and genomic solutions will play a pivotal role in ensuring that innovation is accessible, sustainable, and capable of addressing both national and global challenges. Ultimately, self-reliance in biotechnology is not just about reducing imports—it is about building a resilient ecosystem that empowers scientific discovery, healthcare advancement, and economic growth.

Next-generation sequencing is transforming the industry. How do you see it shaping the future of diagnostics and personalized medicine in India?

Next-generation sequencing (NGS) is poised to be one of the most transformative technologies in India's healthcare and biotechnology landscape. Over the past decade, we have already witnessed its growing adoption across research, diagnostics, and public health, but I believe we are still only at the beginning of its true impact.

In diagnostics, NGS is fundamentally changing the way diseases are identified and understood. Traditional diagnostic approaches often focus on a limited number of genetic markers, whereas NGS enables comprehensive analysis of entire genomes, exomes, transcriptomes, or targeted gene panels in a single workflow. This allows clinicians to identify disease-causing mutations with greater accuracy and speed, particularly in complex conditions such as rare genetic disorders, inherited diseases, and various forms of cancer.

One of the most promising areas is precision oncology. NGS enables detailed molecular profiling of tumors, helping clinicians understand the genetic alterations driving disease progression. This information can guide treatment selection, predict therapeutic response, and support the development of personalized treatment strategies. As targeted therapies become more widely available in India, NGS will play an increasingly important role in clinical decision-making.

In the field of personalized medicine, NGS has the potential to shift healthcare from a reactive model to a predictive and preventive one. By understanding an individual's genetic makeup, healthcare providers can assess disease risk, optimize drug selection through pharmacogenomics, and design more personalized healthcare interventions. This approach has the potential to improve patient outcomes while reducing unnecessary treatments and healthcare costs.

NGS is also expected to significantly advance reproductive and prenatal healthcare. Applications such as carrier screening, non-invasive prenatal testing, preimplantation genetic testing, and newborn screening can help identify genetic risks at an early stage, enabling informed medical decisions and better healthcare planning.

Another important area is infectious disease surveillance and public health. The COVID-19 pandemic demonstrated how genomic sequencing can be used to monitor pathogen evolution, track outbreaks, and support public health responses. Going forward, NGS will remain a critical tool for monitoring emerging infectious diseases and strengthening national health security.

For India specifically, I believe the future impact of NGS will be amplified by our unique genetic diversity. Large-scale genomic initiatives and population-specific studies will generate valuable datasets that improve disease understanding and enable the development of diagnostics and therapies tailored to Indian populations. This will be essential for realizing the full potential of precision medicine in the country.

However, to fully leverage these opportunities, we must continue investing in infrastructure, bioinformatics capabilities, skilled manpower, data interpretation frameworks, and clinician education. Making NGS more affordable and accessible across different regions of India will also be crucial.

As someone who has been actively involved in genomics and sequencing services, I see NGS not merely as a laboratory technology but as a foundational platform that will reshape healthcare delivery in the coming years. It has the potential to make diagnostics more accurate, treatments more personalized, and healthcare more preventive, ultimately improving the quality of life for millions of people across India.

The biotech ecosystem involves researchers, institutions, and industry players. In your view, what is key to building stronger collaboration across these stakeholders?

Building a strong biotechnology ecosystem requires more than scientific excellence—it requires meaningful collaboration among researchers, academic institutions, healthcare organizations, industry partners, startups, and policymakers. In my view, the most important factor is creating a shared vision where all stakeholders work toward translating scientific discoveries into real-world impact.

One of the key challenges today is that research, industry, and healthcare often operate in separate environments with different priorities. Researchers focus on scientific discovery, institutions emphasize education and knowledge generation, while industry focuses on scalability, commercialization, and market needs. Strong collaboration begins when these stakeholders understand each other's objectives and identify common goals.

Industry-academia partnerships are particularly important. Academic institutions generate innovative ideas and fundamental research, while industry provides practical expertise, infrastructure, funding, and pathways for commercialization. When these strengths are combined, promising discoveries can move more efficiently from the laboratory to applications that benefit society.

Another critical element is developing platforms for knowledge exchange. Conferences, workshops, training programs, collaborative research projects, and innovation forums create opportunities for scientists, clinicians, entrepreneurs, and industry professionals to share expertise and build long-term partnerships. These interactions often lead to innovative solutions that may not emerge within isolated organizations.

Skill development is also a major area where collaboration can create significant value. The biotechnology industry requires professionals who are not only technically proficient but also understand regulatory requirements, data analysis, quality systems, and commercialization. Stronger engagement between educational institutions and industry can help ensure that graduates are equipped with the practical skills needed to succeed in today's biotechnology landscape.

Access to shared infrastructure can further strengthen collaboration. Advanced genomics platforms, sequencing facilities, bioinformatics resources, and specialized laboratories often require substantial investment. Collaborative models that allow multiple institutions and organizations to access these resources can improve efficiency and accelerate innovation while reducing duplication of effort.

Government and policy support also play an important role. Effective funding mechanisms, innovation programs, startup support initiatives, and public-private partnerships can encourage stakeholders to work together on projects that address national priorities in healthcare, agriculture, environmental sustainability, and biotechnology innovation.

From my experience in genomics and biotechnology, successful collaborations are ultimately built on trust, transparency, and mutual benefit. When researchers, institutions, and industry partners recognize that they are part of the same innovation ecosystem rather than operating in silos, the outcomes can be transformative.

As India's biotechnology sector continues to grow, I believe that stronger collaboration will be one of the most important drivers of future success. By combining scientific expertise, industrial capabilities, entrepreneurial innovation, and institutional support, we can accelerate research translation, strengthen indigenous innovation, and position India as a global leader in biotechnology and genomics.

As innovation accelerates, how can the industry balance cost, quality, and scalability without compromising scientific standards?

Balancing cost, quality, and scalability is one of the most important challenges facing the biotechnology industry today. As innovation accelerates and technologies become more accessible, organizations must ensure that growth does not come at the expense of scientific rigor, data reliability, or patient outcomes. In my view, achieving this balance requires a combination of robust quality systems, technological innovation, strategic planning, and a strong scientific culture.

First and foremost, quality must remain non-negotiable. In fields such as genomics, molecular diagnostics, and biotechnology research, even minor errors can have significant consequences. Therefore, organizations must establish standardized protocols, validated workflows, quality control checkpoints, and continuous monitoring systems. Scalability should be built upon a strong quality foundation rather than being treated as a separate objective.

Technology and automation play a crucial role in achieving this balance. Automated sample processing, digital laboratory management systems, advanced sequencing platforms, and bioinformatics pipelines can significantly improve efficiency while reducing human error. When implemented correctly, automation allows organizations to increase throughput and reduce operational costs without compromising data quality.

Another important factor is process optimization. Many laboratories focus on acquiring advanced instruments but may overlook workflow efficiency. Careful evaluation of sample handling, resource utilization, turnaround times, and data management can improve productivity and reduce costs while maintaining scientific standards. Continuous process improvement should be an integral part of organizational strategy.

Investment in skilled human resources is equally critical. Even the most advanced technologies require knowledgeable professionals to operate, validate, interpret, and troubleshoot systems. Building teams that understand both the technical and quality aspects of biotechnology ensures that scaling operations does not compromise scientific integrity.

Collaboration and standardization across the industry can also help reduce costs while maintaining quality. Shared infrastructure, collaborative research programs, centralized facilities, and harmonized quality standards can create economies of scale and improve accessibility to advanced technologies, particularly for smaller institutions and emerging organizations.

From a business perspective, sustainability is essential. Organizations must develop models that allow innovation to be commercially viable while remaining accessible to researchers, clinicians, and patients. Cost reduction should come from efficiency, innovation, and optimization—not from compromising validation procedures, quality control measures, or scientific accuracy.

I believe the future of biotechnology belongs to organizations that can successfully integrate scientific excellence with operational efficiency. Innovation, scalability, and affordability are all important, but they must be built upon a foundation of trust, reproducibility, and quality. Ultimately, maintaining high scientific standards is not a barrier to growth—it is what enables sustainable growth and long-term impact in the biotechnology industry.

For young professionals entering the genomics and biotechnology space, what skills and mindset will be most critical to succeed in this evolving landscape?

For young professionals entering genomics and biotechnology, I believe three things are most critical: strong scientific fundamentals, adaptability, and continuous learning.

The field is evolving rapidly, with advancements in sequencing technologies, bioinformatics, AI, and precision medicine. Therefore, beyond technical expertise, professionals should develop problem-solving skills, data interpretation abilities, and an interdisciplinary mindset.

Equally important is the willingness to learn, collaborate, and embrace innovation. Those who can combine scientific knowledge with practical application, communication skills, and business awareness will be best positioned to lead the next generation of biotechnology advancements.

My advice is simple: stay curious, stay adaptable, and never stop learning. The opportunities in genomics and biotechnology have never been greater.

Looking ahead, how do you see India’s role evolving in the global genomics and biotechnology space over the next decade?

Over the next decade, I see India emerging as a global leader in genomics and biotechnology, driven by its strong scientific talent, growing innovation ecosystem, and expanding healthcare and research infrastructure.

India is uniquely positioned to contribute through large-scale genomic studies, affordable diagnostics, indigenous biotechnology solutions, and advancements in precision medicine. Our diverse population provides valuable opportunities for genetic research that can generate insights with global relevance.

I also believe India will play a major role in biotechnology manufacturing, genomic data science, and the development of cost-effective technologies that make advanced healthcare more accessible worldwide. With continued investment in research, infrastructure, talent development, and industry-academia collaboration, India has the potential to move from being a technology adopter to a global innovator and exporter of biotechnology solutions.

The next decade presents an exciting opportunity for India to not only participate in the global biotechnology revolution but to help shape its future.